Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?

Group 1 - Acasti Pharma (ACST) is currently ranked 6 in the Zacks Sector Rank among 1026 companies in the Medical group, indicating strong performance relative to peers [1] - The Zacks Rank for Acasti Pharma is 2 (Buy), suggesting a positive outlook based on earnings estimates and revisions [1] - The Zacks Consensus Estimate for ACST's full-year earnings has increased by 11.6% in the past quarter, reflecting improved analyst sentiment [2] Group 2 - Acasti Pharma has returned 5.9% year-to-date, outperforming the average return of 4.6% for Medical companies [2] - In comparison, Cigna (CI) has shown a year-to-date return of 9.7% and also holds a Zacks Rank of 2 (Buy) [2] - Acasti Pharma belongs to the Medical - Generic Drugs industry, which is ranked 86 in the Zacks Industry Rank, with an average gain of 8.2% year-to-date, indicating slight underperformance relative to its industry [3] Group 3 - Cigna operates in the Medical - HMOs industry, currently ranked 175, which has declined by 6.1% year-to-date [3] - Both Acasti Pharma and Cigna are highlighted as stocks to watch for continued solid performance in the Medical sector [3]